Radiochemistry and Radiation Chemistry Key Laboratory of Fundamental Science, College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, China.
Radiochemistry and Radiation Chemistry Key Laboratory of Fundamental Science, College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, China.
Bioorg Med Chem Lett. 2022 Mar 15;60:128583. doi: 10.1016/j.bmcl.2022.128583. Epub 2022 Jan 25.
Hypoxia imaging agents can play an important role in the tumor treatment by avoiding the worse effect of radiotherapy and chemotherapy due to the tumor hypoxia. Due to the small size and easy coordination, tricarbonyl technetium-99m can be used to label a wide range of imaging agents. In this work, the tricarbonyl Tc labeled small-sized hypoxia imaging agents containing 2-nitroimidazoles were prepared, which have different carbon chain lengths between cyclopentadienyl and 2-nitroimidazole, and which have one or two 2-nitroimidazole groups. The results of S180 cell experiment and biodistribution indicated that these molecules have different hypoxic selectivity. When contains one 2-nitroimidazole, as the carbon chain lengthens, which means the molecular volume becomes larger, hypoxia cellular uptake and selectivity decrease in S180 cell uptake experiment. In biodistribution study in mice bearing S180 tumor, Tc-2 (1-cyclopentadienyl-5-(2-nitro-1H-imidazol-1-yl)-pentan-1-one tricarbonyl Tc complex), which has intermediate carbon chain, is better due to the more complex factors. Its tumor/blood (T/B) ratio is 3.56 ± 0.25, tumor/muscle(T/M) ratio is 1.73 ± 0.29 and tumor uptake is 2.23 ± 0.24%ID/g at 2 h. Comparing to other tricarbonyl technetium complexes containing one 2-nitroimidazole, the complexes in this work have an advantage in tumor/blood ratio and tumor uptake. This suggests that the small-volume cyclopentadienyl may have an advantage when used as a ligand. When contains two 2-nitroimidazole groups, the complex, 1-cyclopentadienyl-5-di(2-(2-nitro-1H-imidazol-1-yl)ethyl)amino-pentan-1-one tricarbonyl Tc complex (Tc-4), has the better results in the cell experiment than those which contain one 2-nitroimidazole group. Thus the hypoxia imaging agent contains two 2-nitroimidazole groups is more advantageous, but further modifications of Tc-4 are needed to improve its clearance rate in the blood, because the increased lipophilicity leads to a decrease in the T/B ratio of Tc-4. In conclusion, small volume hypoxia imaging agents with two 2-nitroimidazole groups may be the trend of development.
乏氧成像剂可以避免肿瘤乏氧导致的放化疗副作用,在肿瘤治疗中发挥重要作用。由于三羰基锝-99m 具有尺寸小、易配位的特点,可用于标记多种成像剂。本工作制备了含有 2-硝基咪唑的三羰基锝标记的小尺寸乏氧成像剂,它们的环戊二烯基和 2-硝基咪唑之间具有不同的碳链长度,并且具有一个或两个 2-硝基咪唑基团。S180 细胞实验和生物分布结果表明,这些分子具有不同的乏氧选择性。当含有一个 2-硝基咪唑时,随着碳链的延长,即分子体积的增大,在 S180 细胞摄取实验中,细胞摄取和选择性降低。在荷 S180 肿瘤小鼠的生物分布研究中,由于更复杂的因素,具有中等碳链的 Tc-2(1-环戊二烯基-5-(2-硝基-1H-咪唑-1-基)戊烷-1-酮三羰基锝配合物)表现更好。其肿瘤/血液(T/B)比值为 3.56±0.25,肿瘤/肌肉(T/M)比值为 1.73±0.29,肿瘤摄取率为 2.23±0.24%ID/g,在 2 h 时。与其他含有一个 2-硝基咪唑的三羰基锝配合物相比,本工作中的配合物在肿瘤/血液比值和肿瘤摄取方面具有优势。这表明,当用作配体时,小体积的环戊二烯基可能具有优势。当含有两个 2-硝基咪唑基团时,配合物 1-环戊二烯基-5-二(2-(2-硝基-1H-咪唑-1-基)乙基)氨基戊烷-1-酮三羰基锝配合物(Tc-4)在细胞实验中的结果优于含有一个 2-硝基咪唑基团的配合物。因此,含有两个 2-硝基咪唑基团的乏氧成像剂更有优势,但需要进一步修饰 Tc-4 以提高其在血液中的清除率,因为亲脂性的增加导致 Tc-4 的 T/B 比值降低。总之,具有两个 2-硝基咪唑基团的小体积乏氧成像剂可能是发展趋势。